|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2019-08-16 |
|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2002-12-31 |
|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期1983-01-01 |
The frequency of uMRD in Japanese patients with CLL after 24 months of treatment with Venetoclax plus/minus Rituximab in the 2L+ in the real-world setting - Japan CLL-MRD study
Immune response to adjuvanted recombinant zoster vaccine in Japanese RA patients treated with upadacitinib - End Zoster-J study
Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults with Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection (GIFT I)
100 项与 Abbvie G.K. 相关的临床结果
0 项与 Abbvie G.K. 相关的专利(医药)
100 项与 Abbvie G.K. 相关的药物交易
100 项与 Abbvie G.K. 相关的转化医学